Antiviral treatment for cirrhosis due to hepatitis C: A review

Singapore Medical Journal

Volumn 53, Issue 4, 2012, Pages 231-235

  Somasundaram, Aravindh ^a   Venkataraman, Jayanthi ^a  

^a STANLEY MEDICAL COLLEGE   (India)

Author keywords

Antiviral treatment; Cirrhosis; Hepatitis C

Indexed keywords

ALBUMIN; ALPHA2B INTERFERON; ALPHA2B INTERFERON PLUS RIBAVIRIN; ANTIVIRUS AGENT; BILIRUBIN; BOCEPREVIR; CREATININE; ELTROMBOPAG; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANEMIA; ASCITES; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE PAIN; CLINICAL TRIAL (TOPIC); DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GENOTYPE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; MUTATION RATE; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PROTHROMBIN TIME; REVIEW; THROMBOCYTOPENIA; VIRAL CLEARANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RECURRENCE;

EID: 84859759032     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. World Health Organization. Hepatitis C. Fact Sheet No. 164. Revised October 2000 [online]. Available at: apps.who.int-fs/en/fact164.html. Accessed August 24, 2009.
2. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusionassociated hepatitis C. N Engl J Med 1995; 332:1463-6.
3. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12 (Pt 1):671-5.
4. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127(Suppl 1):S17-26.
5. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-72.
6. Serfaty L, Aumaǐtre H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-40.
7. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29:1311-6.
8. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31:513-20.
9. Sood A, Midha V, Sood N, Bansal M. Antiviral treatment for chronic hepatitis C: reasons for non-treatment in a Northern Indian center. Indian J Gastroenterol 2006; 25:319-20.
10. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20:103-26.
11. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:1501-6.
12. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebocontrolled trial. N Engl J Med 1989; 321:1506-10.
13. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347-56.
14. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92.
15. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493-9.
16. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002; 347:975-82.
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-65.
18. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
19. Berenguer M. Hepatitis C after liver transplantation: risk factors, outcomes, and treatment. Curr Opin Organ Transplant 2005; 10:81-9.
20. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45:127-43.
21. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103:317-22.
22. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9:S28-34.
23. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-96.
24. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician 2006; 74:756-62.
25. Kamath PS, Kim WR, Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007; 45:797-805.
26. Shah VH, Kamath PS. Portal hypertension and gastrointestinal bleeding. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's gastrointestinal and liver disease. 8th ed. Philadelphia: Saunders, 2006: 1899-934.
27. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-80.
28. Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101:2269-74.
29. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45:579-87.
30. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17:287-92.
31. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-64.
32. Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD practice guidelines: diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
33. Wiesner RH, Sorrell M, Villamil F, International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9:S1-9.
34. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virusinfected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-5.
35. Thomas RM, Bremms JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9:905-15.
36. Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389-96.
37. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42:255-62.
38. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46:206-12.
39. Tekin F, Gunzar F, Karasu Z, Akarca U, Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27:1081-5.
40. Carrión JA, Martínez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50:719-28.
41. Iacobellis A, Siciliano M, Annicchiarico BE, et al. Sustained virological responses following standard anti-viral therapy in decompensated HCVinfected cirrhotic patients. Aliment Pharmacol Ther 2009; 30:146-53.
42. Canonico PG, Kastello MD, Spears CT, et al. Effects of ribavirin on red blood cells. Toxicol Appl Pharmacol 1984; 74:155-62.
43. Curry MP, Afdhal NH. Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis 2005; 9:439-51, vii.
44. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126:1302-11.
45. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227-36.
46. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-38.
47. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-50.
48. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-16.